These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38126937)

  • 1. Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID-19.
    Razzaq A; Disoma C; Zhou Y; Tao S; Chen Z; Liu S; Zheng R; Zhang Y; Liao Y; Chen X; Liu S; Dong Z; Xu L; Deng X; Li S; Xia Z
    Rev Med Virol; 2024 Jan; 34(1):e2500. PubMed ID: 38126937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overactive Epidermal Growth Factor Receptor Signaling Leads to Increased Fibrosis after Severe Acute Respiratory Syndrome Coronavirus Infection.
    Venkataraman T; Coleman CM; Frieman MB
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28404843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 aberrantly elevates mitochondrial bioenergetics to induce robust virus propagation.
    Shin HJ; Lee W; Ku KB; Yoon GY; Moon HW; Kim C; Kim MH; Yi YS; Jun S; Kim BT; Oh JW; Siddiqui A; Kim SJ
    Signal Transduct Target Ther; 2024 May; 9(1):125. PubMed ID: 38734691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis.
    Venkataraman T; Frieman MB
    Antiviral Res; 2017 Jul; 143():142-150. PubMed ID: 28390872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy.
    Sari M; Aydiner A
    J Cancer Res Ther; 2020; 16(1):132-138. PubMed ID: 32362623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant infection by blocking the epidermal growth factor receptor (EGFR) pathway.
    Han Y; Kim S; Park T; Hwang H; Park S; Kim J; Pyun J-c; Lee M
    Microbiol Spectr; 2024 Nov; 12(11):e0158324. PubMed ID: 39291996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perturbed Lipid Metabolism Transduction Pathways in SARS-CoV-2 Infection and Their Possible Treating Nutraceuticals.
    Shukla A; Singh A; Tripathi S
    J Am Nutr Assoc; 2024; 43(7):614-626. PubMed ID: 38805016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation.
    Xu G; Li Y; Zhang S; Peng H; Wang Y; Li D; Jin T; He Z; Tong Y; Qi C; Wu G; Dong K; Gou J; Liu Y; Xiao T; Qu J; Li L; Liu L; Zhao P; Zhang Z; Yuan J
    Cell Res; 2021 Dec; 31(12):1230-1243. PubMed ID: 34663909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Interference between SARS-CoV-2 and Tyrosine Kinase Receptor Signaling in Cancer.
    Purcaru OS; Artene SA; Barcan E; Silosi CA; Stanciu I; Danoiu S; Tudorache S; Tataranu LG; Dricu A
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34063231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Epidermal Growth Factor Receptor Signaling by Antisense Oligonucleotides as a Novel Approach to Epidermal Growth Factor Receptor Inhibition.
    Madanayake TW; Welsh EA; Darville LNF; Koomen JM; Chalfant CE; Haura EB; Robinson TJ
    Nucleic Acid Ther; 2022 Oct; 32(5):391-400. PubMed ID: 35861718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection.
    Lieber CM; Kang H-J; Sobolik EB; Sticher ZM; Ngo VL; Gewirtz AT; Kolykhalov AA; Natchus MG; Greninger AL; Suthar MS; Plemper RK
    J Virol; 2024 Sep; 98(9):e0090524. PubMed ID: 39207133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dihydromyricetin on SARS-CoV-2 viral replication and pulmonary inflammation and fibrosis.
    Xiao T; Wei Y; Cui M; Li X; Ruan H; Zhang L; Bao J; Ren S; Gao D; Wang M; Sun R; Li M; Lin J; Li D; Yang C; Zhou H
    Phytomedicine; 2021 Oct; 91():153704. PubMed ID: 34419736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and Mechanisms of Mucus Accumulation in COVID-19 Lung Disease.
    Kato T; Asakura T; Edwards CE; Dang H; Mikami Y; Okuda K; Chen G; Sun L; Gilmore RC; Hawkins P; De la Cruz G; Cooley MR; Bailey AB; Hewitt SM; Chertow DS; Borczuk AC; Salvatore S; Martinez FJ; Thorne LB; Askin FB; Ehre C; Randell SH; O'Neal WK; Baric RS; Boucher RC
    Am J Respir Crit Care Med; 2022 Dec; 206(11):1336-1352. PubMed ID: 35816430
    [No Abstract]   [Full Text] [Related]  

  • 15. Rapamycin prevents transforming growth factor-alpha-induced pulmonary fibrosis.
    Korfhagen TR; Le Cras TD; Davidson CR; Schmidt SM; Ikegami M; Whitsett JA; Hardie WD
    Am J Respir Cell Mol Biol; 2009 Nov; 41(5):562-72. PubMed ID: 19244201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovatodiolide inhibits SARS-CoV-2 replication and ameliorates pulmonary fibrosis through suppression of the TGF-β/TβRs signaling pathway.
    Chiou WC; Huang GJ; Chang TY; Hsia TL; Yu HY; Lo JM; Fu PK; Huang C
    Biomed Pharmacother; 2023 May; 161():114481. PubMed ID: 36906971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of epidermal growth factor receptor suppresses parathyroid hormone-related protein expression in tumours and ameliorates cancer-associated cachexia.
    Weber BZC; Agca S; Domaniku A; Bilgic SN; Arabaci DH; Kir S
    J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1582-1594. PubMed ID: 35373517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral fibrotic scoring and drug screen based on MAPK activity uncovers EGFR as a key regulator of COVID-19 fibrosis.
    Vagapova ER; Lebedev TD; Prassolov VS
    Sci Rep; 2021 May; 11(1):11234. PubMed ID: 34045585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACE2-EGFR-MAPK signaling contributes to SARS-CoV-2 infection.
    Engler M; Albers D; Von Maltitz P; Groß R; Münch J; Cirstea IC
    Life Sci Alliance; 2023 Sep; 6(9):. PubMed ID: 37402592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2.
    Bowden-Reid E; Ledger S; Zhang Y; Di Giallonardo F; Aggarwal A; Stella AO; Akerman A; Milogiannakis V; Walker G; Rawlinson W; Turville S; Kelleher AD; Ahlenstiel C
    Antiviral Res; 2023 Sep; 217():105677. PubMed ID: 37478918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.